The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase
Open accessAbstract
Purpose: To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance. Methods: Specimen pairs from 39 patients were tissue arrayed and stained for ER, progesterone receptor (PgR), Bcl-2, c-ErbB2 (HER-2), and phosphorylated (p) p38 mitogen-activated protein kinase (MAPK), p-ERK1/2 MAPK, and p-Akt. Xenograft MCF-7 tumors before and after tamoxifen resistance were assessed for levels of p-p38. Results: Pretreatment, there were strong correlations between ER, PgR, and Bcl-2, and an inverse correlation between ER and HER-2. These correlations were lost in the tamoxifen- resistant tumors and replaced by strong correlations between ER and p-p38 and p-ERK. ER expression was lost in 17% of resistant tumors. Three (11%) of the 26 tumors originally negative for HER-2 became amplified and/or overexpressed at resistance. All ER-positive tumors that overexpressed HER-2 originally or at resistance expressed high levels of p-p38. In the pretreatment and tamoxifen-resistant specimens, there were strong correlations between p-p38 and p-ERK. In the tamoxifen-resistant xenograft tumors, like the clinical samples, there was a striking increase in p-p38. Conclusion: The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Self-citationShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Self-citationPhosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Self-citationCharacterization of the Structure and Function of a New Mitogen-activated Protein Kinase (p38β)
Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., & Han, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17920 · Cited by 746
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
HER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Self-citationSchiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
Self-citationAIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Self-citationKuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2584 · Cited by 358
Tamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000115858.45890.53 · Cited by 315
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Self-citationJohnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Self-citationWu, R.-C., Qin, J., Yi, P., Wong, J., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.019 · Cited by 296
Mitogen-Activated Protein Kinase Activation in UV-Induced Signal Transduction
Bode, A. M., & Dong, Z. (2003) · Science's STKE · doi:10.1126/stke.2003.167.re2 · Cited by 295
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., & Nicholson, R. I. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<247::aid-ijc1042>3.0.co;2-s · Cited by 249
Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V., & DeGregorio, M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1477 · Cited by 235
Self-citationCui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo
Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211
Self-citationLee, H., & Bai, W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5835-5845.2002 · Cited by 202
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194
Self-citationJohnston, S. R. D., Lü, B., Scott, G. K., Kushner, P. J., Smith, I. E., Dowsett, M., & Benz, C. C. (1999) · PubMed · Cited by 172
Self-citationDAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells
Hutcheson, I. R., Knowlden, J. M., Madden, T.-A., Barrow, D., Gee, J. M. W., Wakeling, A. E., & Nicholson, R. I. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025484908380 · Cited by 169
Yao, J., Xiong, S., Klos, K., Nguyen, N., Grijalva, R., Li, P., & Yu, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204944 · Cited by 168
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
Nicholson, R. I., McClelland, R. A., Robertson, J. F., & Gee, J. M. (1999) · Endocrine-related cancer · doi:10.1677/erc.0.0060373 · Cited by 160
Altered expression of estrogen receptor coregulators during human breast tumorigenesis.
Murphy, L. C., Simon, S. L., Parkes, A., et al. (2000) · PubMed · Cited by 149
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue
List, H.-J., Reiter, R., Singh, B., Wellstein, A., & Riegel, A. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1017910924390 · Cited by 148
Lee, A. V., Cui, X., & Oesterreich, S. (2001) · PubMed · Cited by 146
Esteva, F. J., Şahin, A. A., Smith, T. L., Yang, Y., Pusztai, L., Nahta, R., Buchholz, T. A., Buzdar, A. U., Hortobágyi, G. N., & Bacus, S. S. (2004) · Cancer · doi:10.1002/cncr.11940 · Cited by 135
Osipo, C., Gajdos, C., Liu, H., Chen, B., & Jordan, V. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg079 · Cited by 131
Lee, H., Jiang, F., Wang, Q., Nicosia, S. V., Yang, J., Su, B., & Bai, W. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.11.0554 · Cited by 104
Multiple progesterone receptor assays in human breast cancer.
Gross, G. E., Clark, G. M., Chamness, G. C., & McGuire, W. L. (1984) · PubMed · Cited by 95
The role of HER-2 expression in predicting response to therapy in breast cancer.
MASS, R. D. (2000) · PubMed · Cited by 92
Petz, L. N., Ziegler, Y., Schultz, J. R., & Nardulli, A. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0105 · Cited by 81
Serine phosphorylation of paxillin by heregulin-β1: role of p38 mitogen activated protein kinase
Vadlamudi, R. K., Adam, L., Talukder, A. H., Mendelsohn, J. M., & Kumar, R. (1999) · Oncogene · doi:10.1038/sj.onc.1203163 · Cited by 65
Johnston, S. R. D., Boeddinghaus, I., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M. G., Grimshaw, R., Jarman, M., & Dowsett, M. (1999) · PubMed · Cited by 58
Self-citationChange in oestrogen receptor expression and function in tamoxifen-resistant breast cancer
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Newby, J. A., & Dowsett, M. (1995) · Endocrine Related Cancer · doi:10.1677/erc.0.0020105 · Cited by 31
Self-citation
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationMeta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1274 · Cited by 813
Self-citationHER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
Self-citation
Metadata
- Authors
- Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-10
- Volume
- 23
- Issue
- 11
- Pages
- 2469-2476
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137355132
- Cited by
- 489
- References
- 47
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.